NCT02378207View on ClinicalTrials.gov

Safety and Immunogenicity Study of BCG, H4:IC31, and H56:IC31 Revaccination in Healthy Adolescents

PHASE1CompletedINTERVENTIONAL

Enrollment

84

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

October 31, 2016

Study Completion Date

December 9, 2016

Conditions

Tuberculosis

Interventions

BIOLOGICAL

H4:IC31

H4 contains Mtb antigens Ag85B and TB10.4

BIOLOGICAL

H56:IC31

H56 contains Mtb antigens ESAT-6, and Rv2660c

BIOLOGICAL

BCG

BIOLOGICAL

Control Sodium Chloride 0.9%

Trial Locations (1)

Unknown

Desmond Tutu HIV Foundation, Cape Town

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

HIV Vaccine Trials Network

NETWORK

collaborator

Sanofi Pasteur, a Sanofi Company

INDUSTRY

collaborator

Statens Serum Institut

OTHER

lead

Aeras

OTHER